Dew,
I've never seen any compiled data per se, but it appears that smaller is better. In all essence isn't that what Novartis is doing? While NVS still has a huge RD budget it really has formed an independent network of mini research centers all over the world, and they have produced great results.
Considering the size of Pfizer, I'd think they'd be better off just operating as an financial center of pharma (which in many ways they have been considering their blockbusters come through acquisitions).
When I think of what large drugs PFE came out with over the past decade I come up with Stutent (purchased), Chantex (mistake)and Lyrica. Those drugs aren't worth $50 billion.
Market Data 
Markets 
AI
